You have read all your free articles, to continue reading subscribe to read the rest of this content.
AlzeCure Pharma has received a response from the US Food and Drug Administration (FDA) regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain. ACD440 completed a positive phase Ib study in 2021 and the company now plans to initiateAlready a…
AlzeCure Pharma has received approval from regulatory authorities in Germany to initiate a clinical Phase Ib study with the drug candidate ACD440. ACD440 is a drug candidate for topical use, i.e as a gel or cream, within AlzeCure's Painless platform and focused on neuropathic pain. ACD440 has preAlready a subscriber…
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg…
Ultimovacs has announced continuing positive topline results in its ongoing US-based Phase I clinical trial evaluating the company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. The trial had Already a subscriber Login You have read all your free…
